$1.4B Zyprexa Deal Could Spark More Qui Tam Suits
Eli Lilly & Co.'s record-breaking $1.4 billion deal to settle charges that it illegally marketed its anti-psychotic treatment Zyprexa for off-label use could stimulate, one observer says, a wave of false...To view the full article, register now.
Already a subscriber? Click here to view full article